Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition

Search Radius:25 Miles

5
10
15
20
25
30
40
50
100
500
All

We've found

6,735

archived clinical trials in

Psoriasis

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Clinical and Translational Research Center of Alabama, PC

mi

from

Tuscaloosa, AL

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

SunValley Arthritis Center Ltd

mi

from

Peoria, AZ

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Arthritis Association of Southern California

mi

from

Los Angeles, CA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

The Regents University of California Los Angeles

mi

from

Los Angeles, CA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Rheumatology Consultants of Delaware dba Delaware Arthritis

mi

from

Lewes, DE

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Center for Arthritis and Rheumatic Diseases

mi

from

Miami, FL

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Coral Research Clinic corp

mi

from

Miami, FL

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Arthritis Research of Florida, Inc.

mi

from

Palm Harbor, FL

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Sarasota Arthritis Research Center

mi

from

Sarasota, FL

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

West Broward Rheumatology Associates, Inc.

mi

from

Tamarac, FL

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

North Georgia Rheumatology Group

mi

from

Lawrenceville, GA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Arthritis Research Center Foundation, NDB

mi

from

Wichita, KA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Ochsner Clinic - Baton Rouge

mi

from

Baton Rouge, LA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Ochsner Clinic Foundation New Orleans

mi

from

New Orleans, LA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Rheumatology and Osteoporosis Specialists

mi

from

Shreveport, LA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

mi

from

Boston, MA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Pine Hollow Partners

mi

from

East Lansing, MI

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

St. Paul Rheumatology, PA

mi

from

Eagan, MN

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Univ of Nebraska Med Ctr

mi

from

Omaha, NE

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

The Center for Rheumatology, LLP

mi

from

Albany, NY

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Mary Imogene Bassett Hospital, Bassett Research Institute

mi

from

Cooperstown, NY

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Ohio State University

mi

from

Columbus, OH

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Altoona Center for Clinical Research

mi

from

Duncansville, PA

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Carolina Health Specialists

mi

from

Myrtle Beach, SC

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Arthritis Associates, PLLC

mi

from

Hixson, TN

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

West Tennessee Research Institute

mi

from

Jackson, TN

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

Southwest Rheumatology Research LLC

mi

from

Mesquite, TX

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

University of Texas Health Science Center at San Antonio

mi

from

San Antonio, TX

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)

Status: Enrolling
Updated: 12/31/1969

West Virginia Research Institute

mi

from

South Charleston, WV

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Mesa, AZ

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

mi

from

Denver, CO

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Palm Harbor, FL

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Sarasota, FL

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Peoria, IL

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Shreveport, LA

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Lincoln, NE

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Albany, NY

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Oklahoma City, OK

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Oklahoma City, OK

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Duncansville, PA

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Greenville, SC

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Mesquite, TX

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Burlington, VT

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Seattle, WA

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Seattle, WA

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Kogarah,

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Saint Clair Shores, MI

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Upland, CA

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigative Site

mi

from

Saint Louis, MO

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)

Status: Enrolling
Updated: 12/31/1969

Novartis Investigational Site

mi

from

Charleston, SC